Pfizer Inc. (NYSE:PFE) shares are trading lower by almost 1% on Monday as the company shared data from Phase 2b studies of berobenatide, an investigational GLP-1 receptor agonist for weight management.

Pfizer Berobenatide Update

On Saturday, the company reported that the Phase 2b studies for berobenatide demonstrated a non-placebo-adjusted weight loss of 15.9% in participants.

The pivotal Phase 3 study is currently open for enrollment, which may further bolster Pfizer’s position in the obesity treatment market.

Pfizer plans to advance 10 Phase 3 studies for berobenatide in 2026 for chronic weight management and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea, as part of a broader program of 20+ obesity trials.

The first clinical experience with the top weekly dose for berobenatide is were presented for the first time.